BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7827902)

  • 41. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
    Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
    Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
    Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Colorectal cancer recurrence in the liver: detection by PET.
    Yasuda S; Makuuchi Y; Sadahiro S; Mukai M; Tokunaga N; Tajima T; Shohtsu A
    Tokai J Exp Clin Med; 1998 Oct; 23(4):167-71. PubMed ID: 10359505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
    Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decision analysis for the cost-effective management of recurrent colorectal cancer.
    Park KC; Schwimmer J; Shepherd JE; Phelps ME; Czernin JR; Schiepers C; Gambhir SS
    Ann Surg; 2001 Mar; 233(3):310-9. PubMed ID: 11224617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of 18F-FDG PET/CT scan in following-up of nasopharyngeal carcinoma after radiotherapy].
    Yu DF; Zuo CT; Dai JZ; Dong MJ; Zhao J; Lin XT; Guan YH
    Ai Zheng; 2004 Nov; 23(11 Suppl):1538-41. PubMed ID: 15566675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
    Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
    ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
    Flamen P; Hoekstra OS; Homans F; Van Cutsem E; Maes A; Stroobants S; Peeters M; Penninckx F; Filez L; Bleichrodt RP; Mortelmans L
    Eur J Cancer; 2001 May; 37(7):862-9. PubMed ID: 11313174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
    Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
    Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
    Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
    Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.